Drug Trial Radar · NCT07295834
Modafinil For Fatigue in IBD
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
May 5, 2026
Primary completion
Dec 1, 2027
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- Imperial College LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guy's and St Thomas' NHS Foundation Trust; King's College Hospital NHS Trust; Imperial College Healthcare NHS Trust; London North West University Health Care NHS Trust
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fatigue is a big problem in people with inflammatory bowel disease (IBD). Even when IBD is well controlled, 50% of patients remain fatigued most of the time. Fatigue can be physical (e.g. feeling tired or weak) and mental (e.g. brain fog). However, there are no effective treatments for IBD fatigue. Modafinil is a medication that can rapidly improve fatigue. It usually acts within 30 minutes and improves wakefulness. It can also improve brain fog. Modafinil has been used for over 30 years in people with narcolepsy, which is a condition where people fall asleep during the day. Modafinil has also been used in people who do not have narcolepsy. This study will compare modafinil with a dummy tablet (placebo) in people with IBD. This is a feasibility study. This means it primarily aims to test whether a trial like this can be conducted in people with IBD. Half of the patients in the study will receive modafinil and half will receive placebo. Treatment will be 12 weeks. Patients will start by taking 1 tablet and will then increase to 2 tablets and then 3 tablets if needed. A computer will randomly allocate treatment, meaning there is an equal chance of being allocated modafinil or placebo. They will be followed up after 6 weeks and 12 weeks. Being a feasibility study, the investigators will measure how many patients consent to the study; how many complete treatment; and how acceptable the treatment is. Participants will complete a range of questionnaires measuring fatigue, mental health and gut health, primarily to look at the completeness and spread of data, and to obtain estimates of treatment effects and their variance. If feasible, this study will support a larger version of the trial.
Conditions
- Crohn Disease (CD)
- Ulcerative Colitis (UC)
- Fatigue
Interventions
ModafinilDrug
100-300mg daily according to patient response
PlaceboDrug
1-3 placebo capsules according to patient response
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recruitment rateTime frame: 2 years
- Trial adherenceTime frame: 12 weeks
- Treatment adherenceTime frame: 12 weeks
- Study procedures acceptability and complianceTime frame: 12 weeks
- Overall acceptabilityTime frame: 12 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Imperial College Healthcare NHS Trust
London, United Kingdom · Recruiting
St Mark's Hospital
London, United Kingdom · Recruiting
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom · Recruiting
King's College Hospital NHS Foundation Trust
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.